- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Sonia Oskouei Explains the Importance of Education Around Biosimilars
Early education and communication are needed for successful uptake of biosimilars, explained Sonia T. Oskouei, PharmD, director, Pharmacy Program Development for Biosimilars, Premier Inc.
Early education and communication are needed for successful uptake of biosimilars, explained Sonia T. Oskouei, PharmD, director, Pharmacy Program Development for Biosimilars, Premier Inc.
Transcript
What are the biggest misconceptions oncologists have with biosimilars?
With oncology, it’s kind of unique a unique therapeutic area where there’s a sense of evaluating products and utilizing them when there’s not as much robust clinical data sometimes. So, the perception, there’s a wide range of it, to see how they’re going to react to these biosimilars, especially with the 3 big oncology agents expected to launch really soon, it’s to be determined how they react to it.
With 4 trastuzumab biosimilars now approved, what efforts are needed to ensure that oncologists are comfortable prescribing these therapies for their patients when they hit the market?
I think this goes back to the core need of education with biosimilars and being proactive with that. What we’ve seen to date for those health systems and providers that have been successful with biosimilars, there’s certain characteristics that make them able to uptake these products faster and be successful. Part of that is early education and communication. We’ve seen health systems do a full roll out of communication and education from nursing, physicians, pharmacy, and patients, and having that information out in advance has helped a lot when those products become available so they’re not backpedaling at that time.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
